Index RUT
P/E -
EPS (ttm) -1.83
Insider Own 58.39%
Shs Outstand 130.33M
Perf Week -0.33%
Market Cap 4.10B
Forward P/E -
EPS next Y -1.87
Insider Trans -0.24%
Shs Float 60.46M
Perf Month -10.19%
Income -243.45M
PEG -
EPS next Q -0.43
Inst Own 46.30%
Short Float 14.07%
Perf Quarter -26.18%
Sales 0.00M
P/S -
EPS this Y -4.71%
Inst Trans 5.05%
Short Ratio 7.39
Perf Half Y -19.35%
Book/sh 4.68
P/B 6.03
EPS next Y -4.20%
ROA -41.70%
Short Interest 8.51M
Perf Year 74.57%
Cash/sh 4.76
P/C 5.94
EPS next 5Y 3.69%
ROE -44.51%
52W Range 15.90 - 45.58
Perf YTD -33.00%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -35.84%
52W High -38.07%
Beta 0.73
Dividend TTM -
Quick Ratio 22.14
Sales past 5Y 0.00%
Gross Margin -
52W Low 77.53%
ATR (14) 1.44
Dividend Ex-Date -
Current Ratio 22.14
EPS Y/Y TTM -10.48%
Oper. Margin 0.00%
RSI (14) 35.52
Volatility 4.26% 4.51%
Employees 164
Debt/Eq 0.00
Sales Y/Y TTM -
Profit Margin -
Recom 1.06
Target Price 50.87
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q 27.65%
Payout -
Rel Volume 0.72
Prev Close 28.80
Sales Surprise -
EPS Surprise 33.09%
Sales Q/Q -
Earnings Feb 12 BMO
Avg Volume 1.15M
Price 28.23
SMA20 -6.74%
SMA50 -13.42%
SMA200 -11.98%
Trades
Volume 507,034
Change -1.99%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-28-24 Initiated
Oppenheimer
Outperform
$50
Mar-13-24 Initiated
Goldman
Buy
$50
Feb-20-24 Initiated
JP Morgan
Overweight
$51
Feb-15-24 Initiated
Wolfe Research
Outperform
$55
Dec-12-23 Initiated
Deutsche Bank
Buy
$50
Oct-13-23 Upgrade
UBS
Neutral → Buy
$18 → $55
Sep-26-23 Upgrade
Raymond James
Mkt Perform → Outperform
$40
May-01-23 Initiated
BofA Securities
Buy
$26
Apr-25-23 Initiated
Citigroup
Buy
$28
Mar-31-23 Initiated
Piper Sandler
Overweight
$28
Mar-30-23 Initiated
Stifel
Buy
$28
Feb-15-23 Initiated
Cantor Fitzgerald
Overweight
$30
Feb-13-23 Upgrade
Guggenheim
Neutral → Buy
$30
Jan-03-23 Upgrade
Wells Fargo
Equal Weight → Overweight
$10 → $27
Sep-26-22 Downgrade
UBS
Buy → Neutral
$7 → $5
Dec-08-21 Initiated
Wells Fargo
Equal Weight
$9
Aug-03-21 Downgrade
Robert W. Baird
Outperform → Neutral
$20 → $10
Aug-02-21 Downgrade
Credit Suisse
Neutral → Underperform
$12 → $7
Jun-01-21 Downgrade
Stifel
Buy → Hold
$28 → $9
Jun-01-21 Downgrade
Guggenheim
Buy → Neutral
Show Previous Ratings
Apr-24-24 11:33AM
07:39AM
Apr-22-24 11:53AM
Apr-17-24 12:00PM
Mar-25-24 03:00PM
04:45PM
Loading…
Mar-21-24 04:45PM
(Investor's Business Daily)
11:31AM
Mar-17-24 05:20PM
Mar-14-24 07:04AM
Mar-13-24 11:30AM
Mar-12-24 07:30AM
Mar-08-24 09:35AM
Feb-26-24 03:04PM
Feb-23-24 11:22PM
Feb-14-24 04:35AM
12:29AM
Loading…
12:29AM
(Thomson Reuters StreetEvents)
Feb-13-24 07:26AM
Feb-12-24 07:00AM
Feb-06-24 02:38PM
Jan-22-24 06:07AM
Jan-19-24 04:39PM
Jan-13-24 03:02AM
Jan-03-24 08:00AM
Dec-26-23 10:01AM
Dec-21-23 04:09PM
(Investor's Business Daily) +8.07%
11:00AM
10:57AM
06:49AM
Dec-20-23 04:30PM
04:30PM
10:16AM
Loading…
Dec-19-23 10:16AM
Dec-01-23 01:01AM
Nov-29-23 10:22AM
Nov-28-23 07:00AM
07:00AM
Nov-25-23 11:03AM
Nov-14-23 12:30AM
(Thomson Reuters StreetEvents) +6.62%
Nov-13-23 08:00AM
Nov-10-23 07:19AM
Nov-09-23 08:17AM
07:00AM
Oct-27-23 11:02PM
Oct-13-23 09:50AM
Oct-11-23 11:01PM
Oct-07-23 01:00AM
Oct-05-23 03:01AM
Oct-02-23 04:52PM
Sep-28-23 09:58AM
Sep-27-23 11:41PM
04:09PM
(Investor's Business Daily)
04:06PM
(Investor's Business Daily)
12:25PM
(Investor's Business Daily)
12:21PM
09:25AM
Sep-26-23 05:00PM
04:13PM
(Investor's Business Daily)
04:06PM
03:23PM
02:26PM
10:01AM
(Investor's Business Daily)
09:10AM
06:00AM
Sep-25-23 11:01PM
Aug-17-23 09:31AM
Aug-12-23 08:25AM
Aug-11-23 11:20AM
Aug-10-23 07:00AM
Aug-09-23 06:26AM
Aug-01-23 10:00AM
Jul-03-23 09:00AM
Jul-01-23 09:00AM
Jun-29-23 01:42AM
(Thomson Reuters StreetEvents)
Jun-21-23 11:30AM
May-23-23 09:48AM
06:05AM
May-22-23 07:00AM
Apr-05-23 01:45PM
Feb-15-23 01:14PM
Feb-03-23 07:00AM
Dec-29-22 11:04AM
Dec-19-22 07:53AM
Dec-16-22 08:06AM
Dec-15-22 09:40AM
Dec-12-22 03:44PM
Nov-25-22 09:40AM
Nov-24-22 11:04AM
Nov-17-22 10:38AM
Nov-09-22 09:40AM
Nov-07-22 01:34PM
08:00AM
Nov-04-22 07:00AM
Oct-20-22 01:56PM
Oct-09-22 10:57AM
Oct-06-22 03:52PM
Oct-04-22 08:45AM
Sep-29-22 02:36PM
Sep-28-22 10:45AM
Sep-26-22 04:41PM
Sep-21-22 08:00AM
Sep-09-22 08:00AM
Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Salzmann Peter Chief Executive Officer Apr 17 '24 Sale 29.06 34,079 990,269 1,052,879 Apr 19 05:57 PM Barnett Eva Renee Chief Financial Officer Apr 17 '24 Sale 29.06 12,253 356,049 359,456 Apr 19 06:01 PM Butchko Julia G. Chief Development Officer Apr 17 '24 Sale 29.06 10,115 293,923 451,627 Apr 19 05:59 PM Levine Mark S. Chief Legal Officer Apr 17 '24 Sale 29.06 9,827 285,554 347,119 Apr 19 06:06 PM Macias William L. Chief Medical Officer Apr 17 '24 Sale 29.06 8,280 240,602 377,650 Apr 19 06:05 PM Salzmann Peter Chief Executive Officer Apr 09 '24 Sale 31.18 4,807 149,882 1,086,958 Apr 10 04:14 PM Barnett Eva Renee Chief Financial Officer Apr 09 '24 Sale 31.18 3,689 115,023 371,709 Apr 10 04:18 PM Butchko Julia G. Chief Development Officer Apr 09 '24 Sale 31.18 1,053 32,833 461,742 Apr 10 04:16 PM Salzmann Peter Chief Executive Officer Feb 22 '24 Sale 36.15 13,454 486,362 931,231 Feb 23 04:11 PM Barnett Eva Renee Chief Financial Officer Feb 22 '24 Sale 36.15 2,930 105,920 320,420 Feb 23 04:21 PM Macias William L. Chief Medical Officer Feb 22 '24 Sale 36.15 2,221 80,289 330,952 Feb 23 04:16 PM Butchko Julia G. Chief Development Officer Feb 22 '24 Sale 36.15 2,146 77,578 407,817 Feb 23 04:14 PM Levine Mark S. Chief Legal Officer Feb 22 '24 Sale 36.15 2,134 77,144 301,968 Feb 23 04:18 PM Geffner Michael Chief Medical Officer Jan 26 '24 Sale 37.92 10,101 383,012 89,899 Jan 29 04:11 PM Levine Mark S. Chief Legal Officer Jan 26 '24 Sale 37.92 3,027 114,778 304,102 Jan 29 04:12 PM Macias William L. Chief Medical Officer Jan 18 '24 Sale 41.03 424 17,397 333,173 Jan 19 04:04 PM Barnett Eva Renee Chief Financial Officer Jan 11 '24 Sale 41.83 3,515 147,023 323,350 Jan 12 04:34 PM Salzmann Peter Chief Executive Officer Jan 05 '24 Sale 38.59 3,824 147,568 944,685 Jan 09 04:18 PM Butchko Julia G. Chief Development Officer Jan 05 '24 Sale 38.59 1,297 50,051 409,963 Jan 09 04:20 PM MIGAUSKY GEORGE V Director Dec 01 '23 Sale 39.73 12,700 504,567 109,808 Dec 05 04:25 PM Fromkin Andrew J. Director Dec 01 '23 Sale 39.73 12,350 490,697 88,658 Dec 05 04:30 PM Pande Atul Director Dec 01 '23 Sale 39.73 12,350 490,667 83,158 Dec 05 04:28 PM Salzmann Peter Chief Executive Officer Nov 22 '23 Sale 32.78 16,217 531,581 948,509 Nov 24 02:55 PM Barnett Eva Renee Chief Financial Officer Nov 22 '23 Sale 32.78 4,055 132,920 326,865 Nov 24 02:51 PM Butchko Julia G. Chief Development Officer Nov 22 '23 Sale 32.78 3,265 107,024 411,260 Nov 24 02:47 PM Macias William L. Chief Medical Officer Nov 22 '23 Sale 32.78 3,265 107,024 333,597 Nov 24 02:45 PM Levine Mark S. Chief Legal Officer Nov 22 '23 Sale 32.78 3,252 106,598 307,129 Nov 24 02:41 PM Levine Mark S. Chief Legal Officer Oct 25 '23 Sale 34.66 4,107 142,349 310,381 Oct 27 04:04 PM Macias William L. Chief Medical Officer Oct 19 '23 Sale 36.80 530 19,504 336,862 Oct 20 04:06 PM Barnett Eva Renee Chief Financial Officer Oct 10 '23 Sale 36.92 4,557 168,244 330,920 Oct 11 04:11 PM Salzmann Peter Chief Executive Officer Oct 05 '23 Sale 36.24 5,239 189,887 964,726 Oct 06 05:10 PM Butchko Julia G. Chief Development Officer Oct 05 '23 Sale 36.24 1,735 62,885 414,525 Oct 06 05:15 PM Roivant Sciences Ltd. Director Oct 02 '23 Buy 38.00 1,526,316 58,000,008 79,805,331 Oct 04 05:15 PM Salzmann Peter Chief Executive Officer Aug 30 '23 Sale 22.02 56,774 1,250,338 969,965 Sep 01 04:08 PM Barnett Eva Renee Chief Financial Officer Aug 24 '23 Sale 20.30 14,386 292,036 335,477 Aug 25 05:03 PM Macias William L. Chief Medical Officer Aug 24 '23 Sale 20.30 12,333 250,360 337,392 Aug 25 04:57 PM Butchko Julia G. Chief Development Officer Aug 24 '23 Sale 20.30 12,333 250,360 416,260 Aug 25 05:00 PM Levine Mark S. Chief Legal Officer Aug 24 '23 Sale 20.30 12,286 249,406 314,488 Aug 25 05:05 PM Salzmann Peter Chief Executive Officer Aug 14 '23 Sale 21.42 103,058 2,207,178 1,026,739 Aug 16 04:11 PM Salzmann Peter Chief Executive Officer Aug 07 '23 Sale 21.73 101,339 2,202,096 1,129,797 Aug 08 04:44 PM Levine Mark S. Chief Legal Officer Jul 26 '23 Sale 21.63 3,917 84,725 326,774 Jul 27 04:33 PM Barnett Eva Renee Chief Financial Officer Jul 19 '23 Sale 24.94 2,725 67,962 349,863 Jul 20 04:35 PM Macias William L. Chief Medical Officer Jul 19 '23 Sale 24.94 426 10,624 349,725 Jul 20 04:37 PM Salzmann Peter Chief Executive Officer Jul 12 '23 Sale 19.73 3,233 63,787 1,231,136 Jul 13 05:11 PM Butchko Julia G. Chief Development Officer Jul 12 '23 Sale 19.73 1,470 29,003 428,593 Jul 13 05:10 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite